Vimarsana
Biggest News Aggregation in the World

Page 7 - Kumar Budur News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kumar Budur. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kumar Budur Today - Breaking & Trending Today

HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION - Vimarsana News

HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION

PLYMOUTH MEETING, Pa., July 20, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with...

Phase 3 Study of Pitolisant in Prader-Willi Syndrome to Begin - Vimarsana News

Phase 3 Study of Pitolisant in Prader-Willi Syndrome to Begin

The study will further investigate pitolisant in patients with Prader-Willi syndrome experiencing excessive daytime sleepiness.

Harmony Presents Data on Pitolisant for Prader-Willi Syndrome - Vimarsana News

Harmony Presents Data on Pitolisant for Prader-Willi Syndrome

Harmony presented data from a phase 2 study evaluating pitolisant for the treatment of EDS in people with Prader-Willi syndrome.

HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023 - Vimarsana News

HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative...

Harmony Hits Enrollment Target for Study of Pitolisant for IH - Vimarsana News

Harmony Hits Enrollment Target for Study of Pitolisant for IH

Harmony Biosciences has completed enrollment for its phase 3 INTUNE study of pitolisant in adult patients with idiopathic hypersomnia.